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Abstract: Insomnia disorder is a common complaint of sleep disruption that impacts daytime 
performance and reduces quality of life. Insomnia is generally characterized by subjective reports 
of difficulty obtaining adequate sleep accompanied by daytime impairment. This review provides 
a brief overview of the classification, epidemiology, etiology, and models of the development of 
adult insomnia. The contemporary evidence base for cognitive behavioral therapy in insomnia 
is then reviewed, with a focus on sleep and daytime functioning. The review concludes with a 
discussion of emerging therapies, based on psychological/behavioral principles.
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Classification of insomnia
The American Psychiatric Association’s Diagnostic and Statistical Manual of Men-
tal Disorders, Fifth Edition (DSM-5)1 defines insomnia in adults as a complaint of 
dissatisfaction with sleep quantity or quality, associated with one (or more) of the 
following symptoms: 1) difficulty initiating sleep; 2) difficulty maintaining sleep 
characterized by frequent awakenings or problems returning to sleep after awakenings; 
or 3) early-morning awakening with inability to return to sleep. The sleep disturbance 
must also significantly impact on daytime functioning (social, occupational, educa-
tional, or academic) and occur at least three nights per week for at least three months. 
The impairment must also not be attributable to another disorder or explained by 
substance use.1 The DSM-5 no longer refers to “primary” and “secondary” insomnia, 
but considers insomnia to be a disorder in its own right when both nighttime and 
daytime criteria are met (regardless of comorbidity).1 Recently, the International Clas-
sification of Sleep Disorders, Third Edition (ICSD-3) has also moved toward defining 
insomnia under a more general and inclusive term of “insomnia disorder”.2 Further 
refinements to the ICSD-3 criteria also include the removal of certain phenotypes of 
insomnia and an emphasis on daytime cognitive impairments (ie, working memory 
and attention;2,3 Table 1).
Epidemiology
Estimates of insomnia suggest that approximately one-third of adults report insomnia 
symptoms, making insomnia the most prevalent sleep disorder.1 Of those who suf-
fer from insomnia, 10% will go on to develop chronic insomnia and will complain 
of insomnia in primary health care settings. These individuals also report daytime 
impairments due to poor sleep.4–6ChronoPhysiology and Therapy 2014:4 submit your manuscript | www.dovepress.com
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Table 1 Criteria for insomnia disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition1 and the 
International Classification of Sleep Disorders, Third Edition2
DSM-5: insomnia disorder ICSD-3: chronic insomnia disorder
Sleep A predominant complaint of dissatisfaction with sleep quantity  
or quality, associated with one (or more) of the following  
symptoms: 1) difficulty initiating sleep, 2) difficulty maintaining  
sleep, characterized by frequent awakenings or problems  
returning to sleep after awakenings, and 3) early-morning  
awakening with inability to return to sleep.
The patient reports (or the patient’s parent or caregiver 
reports) marked concern about, or dissatisfaction with, sleep 
comprising one or more of the following: 1) difficulty initiating 
sleep, 2) difficulty maintaining sleep, 3) waking up earlier than 
desired, 4) resistance in going to bed on the appropriate 
schedule, and 5) difficulty sleeping without the parent  
or caregiver present.
Consequences The sleep disturbance causes clinically significant distress  
or impairment in social, occupational, educational, academic,  
behavioral, or other important areas of functioning.
The patient reports (or the patient’s parent or caregiver 
reports) one or more of the following as being associated 
with the nighttime sleep difficulty in fatigue; mood disturbance; 
interpersonal problems; reduced cognitive function; reduced 
performance; daytime sleepiness; behavioral problems  
(eg, hyperactivity, impulsivity, aggression); reduced  
motivation/initiative; proneness to errors/accidents.
Frequency The sleep difficulty occurs at least 3 nights per week. The sleep disturbance and associated daytime symptoms occur 
at least 3 times per week.
Chronicity The sleep difficulty is present for at least 3 months. The sleep disturbance and associated daytime symptoms have 
been present for at least 3 months.
exclusions The sleep difficulty occurs despite adequate opportunity for sleep.
The insomnia is not better explained by and does not occur  
exclusively during the course of another sleep/wake disorder  
(eg, narcolepsy, a breathing-related sleep disorder, a circadian  
rhythm sleep/wake disorder, a parasomnia).
The insomnia is not attributable to the physiological effects  
of a substance (eg, a drug of abuse, a medication).
Coexisting mental disorders and medical conditions do not  
adequately explain the predominant complaint of insomnia.
The reported sleep/wake complaints cannot be explained 
purely by inadequate opportunity (ie, enough time is allotted 
for sleep) or inadequate circumstances (ie, the environment  
is safe, dark, quiet, and comfortable) for sleep.
The sleep/wake difficulty is not better explained by another 
primary sleep disorder.
Abbreviations: DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; iCSD-3, International Classification of Sleep Disorders, Third Edition.
Prevalence varies widely depending upon criteria 
emp  loyed and whether it is considered a symptom of another 
disorder or an independent disorder. Frequently, insomnia 
is documented as a comorbid condition linked to another 
medical or psychiatric condition. For example, around half 
of individuals presenting with insomnia symptoms will 
also present with another psychiatric disorder.1 Insomnia 
is also more prevalent in females than males, with a ratio 
of about 1.44:1 and in those with lower social economic 
status.7 However, further epidemiological research is now 
required in order to elucidate the prevalence, natural history, 
and incidence of insomnia through time with longitudinal 
population-based cohort studies. This will enable researchers 
to understand if insomnia can be prevented and associated 
morbidity reduced.8 Insomnia is also a risk factor for comor-
bid medical and psychiatric disorders, including anxiety and 
depression.9–11
Etiology and models of insomnia
Insomnia is commonly conceptualized through a diathesis 
stress model referred to as the “3P model of insomnia”.12 This 
model aims to provide a framework for the development and 
maintenance of chronic insomnia.13,14 The 3P model describes 
predisposing (behavior and genetic predisposition), precipi-
tating (significant and often traumatic life events that may 
act as a trigger for insomnia), and perpetuating (behavior, 
mood, thoughts, and beliefs) factors that may contribute to 
both the development and maintenance of insomnia over 
time (Figure 1).
Spielman and Glovinsky15 suggest that certain individu-
als may be more vulnerable to the development of insomnia, 
depending upon predisposing factors like a heritable suscep-
tibility to stress. Precipitating events can increase the likeli-
hood of the development of insomnia in certain vulnerable or 
“at-risk” individuals and families. This may set off a period 
of poor sleep or acute short-term (1 month) insomnia. It is 
suggested that insomnia is maintained through perpetuating 
factors that reflect how an individual attempts to cope with 
sleep loss. For example, time in bed may be extended to 
increase the probability of achieving sleep. This, however, 
results in more time awake when in bed and more fragmented 
sleep due to a reduced homeostatic sleep drive. Time spent 
in bed may also vary day-to-day as the individual adjusts 
their sleep habits depending on the quality/quantity of sleep ChronoPhysiology and Therapy 2014:4 submit your manuscript | www.dovepress.com
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previously achieved. This may then disrupt the circadian 
rhythm and also the predictability of sleep.12
In the development of insomnia, conditioned cues nor-
mally associated with sleep (eg, bed, bedroom, bedtime, 
increasing darkness) can become paired with wake activities 
or those that are not normally involved in sleep (eg, work 
or computer use). This results in faulty conditioning of mal-
adaptive sleep habits, reinforcing symptoms of insomnia, 
preventing sleep onset, and possibly increasing sensitivity to 
further sources of disruption (noise, light, or temperature). 
Stimulus control therapy (SCT) and behavioral treatment for 
insomnia seeks to break these negative associations with the 
sleep environment. Attentional biases toward bedroom- and 
sleep-related stimuli have been described and are thought 
to provoke a conditioned response.16 Cognitive models of 
insomnia also posit that insomnia is maintained by dysfunc-
tional cognitive processes, including excessive worry, anxi-
ety, and catastrophizing, which negatively impact on sleep. 
Indeed, Harvey17 suggests that in line with anxiety literature, 
attention needs to be placed on daytime factors in insomnia 
that equally disrupt nighttime sleep. Those with insomnia 
may overestimate daytime performance deficits and this may 
cause increased anxiety over sleep loss and in turn reinforce 
worry regarding obtaining enough sleep.17
Both cognitive and neurocognitive models of insomnia 
build on the initial behavioral perspective and recognize 
that insomnia is precipitated by stressful life events.18 
  Neurocognitive models argue that increased cortical arousal 
(measured through cerebral electroencephalographic rhythms) 
cause increased sensory/information processing and disrupt 
sleep initiation and maintenance.18 This increased sensory/
information processing appears to contribute to an attenuated 
mesograde amnesia of sleep in insomnia or reduced forgetting 
of sleep.18,19 Sleep is therefore difficult to accurately quantify 
in insomnia; however, a number of different measures can be 
used including sleep diaries, actigraphy, and overnight sleep 
studies.20 Once conditioned arousal has set in, it potentially 
perpetuates long-term insomnia through preoccupation 
of sleep. This has previously been proposed as part of an 
attention–intention–effort pathway, which highlights that 
when increased effort is placed on attempting sleep, this in 
turn may cause further sleep loss due to the disruption of the 
automaticity of sleep.16,21 Cognitive behavioral therapy for 
insomnia (CBT-I) looks to address this increased sleep effort 
by modifying thoughts, beliefs, and behaviors of sleep.22
Treatment of insomnia
Evidence-based treatment and management for adult 
insomnia can be distilled into two mainstay modalities: 
1) pharmacotherapy or 2) CBT-I. Prior to seeking treatment 
directly from a health care professional (many with insomnia 
do not seek treatment), individuals often report attempting 
alcohol, over-the-counter medications (eg, antihistamines), 
or herbal/dietary interventions to alleviate symptoms.23,24 
Non-evidence-based treatments for insomnia, however, do 
have the potential to further disrupt sleep and may cause harm 
and/or dependence (eg, alcohol, marijuana).
Pharmacotherapy
In primary care settings, insomnia is generally treated with 
prescription medications such as benzodiazepines (eg, 
temazepam, flurazepam). Despite a recent fall in prescribing 
benzodiazepines, overall hypnotic prescription rates have 
increased due to a rise in non-benzodiazepine receptor ago-
nists or “z-drugs” (eg, zolpidem, zaleplon, eszopiclone).25 
Z-drugs are thought to be more effective due to functional 
selectivity for specific receptor subunits and are also safer 
with a shorter half-life than benzodiazepines. However, there 
is a lack of evidence for less adverse effects, potential for tol-
erance, or long-term effectiveness (.4 weeks).26,27 Sedative 
aids such as antihistamines (doxylamine) and melatonin 
receptor agonists can also be used to treat insomnia. Mela-
tonin has been approved in those over 55 years in the UK for 
short-term use (,4 weeks) but evidence is lacking regarding 
the effectiveness of melatonin in the long term.28 A number 
of off-label agents are often used to treat insomnia despite a 
paucity of evidence, including antidepressants (eg, trazodone, 
trimipramine, doxepin), antipsychotics (eg, quetiapine), and 
anticonvulsants (eg, gabapentin).28 Newer pharmacotherapy 
strategies now look to target the hypocretin/orexin receptor 
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Figure 1 Factors contributing to the development of insomnia, according to the 
3P framework.
Notes: Threshold refers to the probable intensity of insomnia to be classified as   
a “case”. Reprinted from elsevier Health Sciences, espie CA, Kyle SD, Cognitive 
and  behavioural  psychological  therapies  for  chronic  insomnia,  in:  Therapy  in 
Sleep Medicine, Barkoukis TJ, Matheson JK, Ferber R, Dohramji K (ed.), 161–171, 
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antagonist with suvorexant, which appears beneficial in the 
short term (first 4 weeks).29,30
CBT-i
The main nonpharmacological treatment for insomnia is 
CBT-I, which is an evidence-based psychological interven-
tion, usually delivered by a psychologist individually, in small 
groups, or through automated web-based programs.31,32 CBT-I 
seeks to manage insomnia by targeting maladaptive thoughts, 
behaviors, and beliefs about sleep.33 CBT-I is a multicompo-
nent approach and in the context of clinical trials improves 
sleep in 70% of insomnia patients.9,34 CBT-I has been found 
to have similar benefits to pharmacotherapy in the short term 
but with lasting treatment effects over pharmacotherapy,27,35 
and is considered the first-line treatment for insomnia by the 
American Academy of Sleep Medicine,24 National Institutes 
of Health,36 and British Association of Psychopharmacolo-
gy.37 Furthermore, the effectiveness of CBT-I is not moderated 
by factors including: age, sex, hypnotics, or comorbidity.24,38 
The overall approach consists of five main treatment strate-
gies (Table 2).
CBT-I now has meta-analytical evidence to suggest robust 
improvements in subjective measures of sleep (Figure 2). 
Sleep diaries have been found to show medium-to-large 
effect size (ES) improvements (range d=0.77–1.13 pre-to-post 
treatment) for outcome measures, including sleep onset 
latency (SOL), wake time after sleep onset (WASO), and 
sleep efficiency (%SE: the ratio of time spent in bed asleep). 
Total sleep time (TST) was also found to improve with a small 
ES (d=0.29).39 In a meta-analysis, Ho et al40 recently found 
that self-help CBT-I improved sleep, anxiety, and depressive 
symptoms with medium-to-large ES scores for %SE (d=0.80), 
SOL (d=0.66), and WASO (d=0.55). Interestingly the dropout 
rate for self-help CBT-I was comparable to   therapist-delivered 
CBT-I (14.5% versus 16.7%, respectively).40 Similar results 
have been documented previously as Irwin et al41 and   Okajima 
et al42 also found medium-to-large ES improvements for 
SOL (d=0.52 and d=0.67, respectively) and %SE (d=0.52 
and d=0.89, respectively) and medium-to-large ES reduc-
tions for WASO (d=0.64 and d=0.70). Small-to-medium 
ES increases were also found across meta-analytic studies 
for TST (range d=0.17–0.46).35,41,42 Objectively defined 
sleep variables (polysomnography and actigraphy) have 
also shown small-to-moderate effects after CBT-I in meta-
analytical studies, including SOL (d=0.58), WASO (d=0.57), 
and %SE (d=0.47);42 however, measures of objective sleep 
are generally lacking in studies. Further studies adequately 
quantifying objective measures before, after, and at follow-up 
(12 months) are now required as part of randomized controlled 
trials (RCTs) to evaluate whether objective outcomes of 
therapy are sustained long term.
Daytime functioning
Given that daytime dysfunction is attributed to poor sleep in 
insomnia, it would seem important for trials to examine both 
nighttime and daytime outcomes pre-to-post CBT-I. However, 
Table 2 Psychological and behavioral therapies for insomnia
Treatment (level of endorsement)
Stimulus control therapy (standard)
Behavioural recommendations designed to reinforce the association between the bed or bedroom and sleep, and to strengthen a consistent sleep-
wake schedule: (a) go to bed only when sleepy; (b) get out of bed when unable to sleep; (c) use the bed for sleep only (no reading, problem-solving in 
bed); (d) arise at the same time every morning; (e) avoid napping.
Sleep restriction therapy (guideline)
A method that limits the time spent in bed as close as possible to the actual sleep time, thereby producing a mild sleep deprivation, which results in 
more consolidated sleep. The sleep window is gradually increased throughout a few days or weeks until optimum sleep duration is achieved.
Relaxation training (standard)
Clinical procedures aimed at reduction of somatic tension (eg, progressive muscle relaxation, autogenic training) or intrusive thoughts (eg, imagery 
training, meditation) interfering with sleep. Most relaxation techniques need professional guidance initially and daily practice for a few weeks.
Cognitive therapy (insufficient evidence as single therapy)
Psychotherapeutic method aimed at alleviating excessive worries and revising misconceptions about sleep, insomnia, and daytime consequences. 
Specific targets include unrealistic sleep expectations, fear of the consequences of insomnia, and misconceptions of the causes of insomnia.
Sleep hygiene education (insufficient evidence as single therapy)
General guidelines about health practices (eg, diet, exercise, substance use) and environmental factors (eg, light, noise, temperature) that might 
promote or interfere with sleep: (a) avoid stimulants (eg, caffeine, nicotine) for several hours before bedtime; (b) avoid alcohol around bedtime as 
it fragments sleep during the second half of the night; (c) exercise regularly, it can deepen sleep; (d) do not watch the clock; (e) keep the bedroom 
environment dark, quiet, and comfortable.
Cognitive behavioural therapy (standard)
A combination of any of the above behavioural (eg, sleep restriction, stimulus control instructions, relaxation) and cognitive procedures.
Note: Reprinted from The Lancet, 379(9821), Morin CM, Benca R, Chronic insomnia. Lancet, 1129–1141, Copyright © 2012, with permission from elsevier.9ChronoPhysiology and Therapy 2014:4 submit your manuscript | www.dovepress.com
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in general, CBT-I treatment studies have rarely assessed 
and/or reported daytime functioning outcomes. Indeed, since 
the last recommendations for a standard research assessment 
of insomnia formulated by 25 experts and published in 2006, 
no CBT-I treatment study has reported all of the recommended 
“essential” measures suggested by this group.43,44 Therefore, 
more studies are now required to not only evaluate sleep but 
also measures of daytime functioning in response to CBT-I. 
Generally, in the studies that have attempted to measure day-
time functioning, improvements have been found for subjec-
tive measures of anxiety, depression, fatigue, and quality of 
life.45–49 However, a number of studies have also failed to find 
any clinically significant treatment improvements. This may 
be due to the use of generic measures (eg, the Short Form-36 
Health Survey: a measure of health related quality of life) that 
do not sufficiently take into account the specific domains of 
functioning relevant to the individual50 and/or because the 
patients sampled are relatively healthy, making it difficult to 
document a significant effect of treatment.44
Treatment studies should now look to also measure 
subjective daytime functioning in those with insomnia and 
in response to CBT-I. This is due to the fact that insomnia 
requires an explicit impairment of daytime functioning for it 
to be considered a disorder1,2 and a true 24-hour problem that 
impacts on both sleep and wake. Daytime impairments can 
include global complaints of functioning in areas of social, 
occupational, or relationship functioning or can also present 
as a more specific complaint in areas of mood, concentration, 
impaired memory performance, or fatigue for example.1,2,51–53 
It is also thought that these daytime impairments contribute to 
reduced ratings of overall health-related quality of life49 and 
drive treatment-seeking behavior.54 In addition to subjective 
reports, objective assessments of neurocognition and emotion 
perception may also be considered as dependent variables in 
light of documented impairments.3,55,56
Treatment delivery of CBT-i
The primary problem with CBT-I is accessing treatment and 
this is due to a shortage of trained health care professionals 
who can deliver CBT-I. CBT-I can be delivered in a number 
of different procedures and it is this aspect of the literature 
that has received recent attention. Historically, a clinical 
psychologist trained specifically in CBT-I would deliver 
treatment. However, the volume of patients seeking treatment 
for insomnia and the limited number of trained psychologists 
means that access to therapy is difficult.31 Stepped care is 
potentially an extremely useful and cost effective frame-
work for the dissemination of CBT-I. This strategy aims 
to treat the majority of patients with minimal entry level 
treatments that are less costly and easier to deliver than full 
CBT-I (eg, Internet delivered,57 self-help booklets,58 brief 
therapies;59 Table 3). Nonresponders who present with more 
complex problems are able to refer up to higher levels of 
treatment that are more resource intensive and delivered by 
a specialist trained in behavioral sleep medicine.31,32
Strategies to deliver a stepped care service effectively in 
primary care based-settings taking account of both time and 
personnel factors are now required. To address this, studies have 
attempted to manualize therapy with nurse   practitioners47,60 in 
order to provide brief primary care “friendly” versions of 
CBT-I.59 Buysse et al61 found that the delivery of sleep restric-
tion therapy (SRT) plus SCT for insomnia over two sessions 
and two follow-up telephone calls produced significantly better 
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Figure 2 effect sizes for psychological and behavioral interventions pre-to-post 
treatment and at follow-up (average of 6 months) for cognitive behavioral therapy 
for insomnia.
Note: Reprinted from Sleep Medicine Reviews, vol 13, issue 3, Riemann D, Perlis ML, 
The treatments of chronic insomnia: A review of benzodiazepine receptor agonists 
and psychological and behavioral therapies, Pages 205–214.27 Copyright © 2008, 
with permission from elsevier.
Abbreviations: NOA, number of awakenings; SL, sleep latency; TST, total sleep 
time; wASO, wake time after sleep onset.
Table 3 Treatment modalities of cognitive behavioral therapy for 
insomnia and key controlled trials
Group therapy espie et al47,76,77
Large group therapy Jernelov et al78
individual therapy Morin et al34
Brief therapy edinger and Sampson59
Telephone-delivered Arnedt et al79
internet-delivered espie et al57
Self-help books Jernelov et al78
Self-help booklets Morgan et al58ChronoPhysiology and Therapy 2014:4 submit your manuscript | www.dovepress.com
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outcomes in sleep diary and actigraphic measures of sleep 
compared to a sleep information control condition in older 
adults with insomnia. Gains were also maintained at 6 months 
follow-up. More recently, studies have looked to evaluate the 
individual contributions of behavioral and cognitive-based 
approaches of overall CBT-I.62
Stand-alone behavioral components of CBT-I have been 
evaluated recently as part of a dismantling approach to insom-
nia treatment. As part of an RCT, Epstein et al63 assessed the 
contribution of multicomponent therapy (consisting of SRT 
plus SCT with no structured cognitive approach) compared 
to SRT, SCT, and waitlist control groups. The study found 
SCT plus SRT to be as effective as multicomponent therapy 
and suggests that individual behavioral treatment options 
may be powerful stand-alone interventions.64,65 Indeed, such 
components may be delivered more rapidly than overall CBT-I 
in primary care settings by trained nurse practitioners or 
Masters level therapists as part of a stepped care framework.31 
Therefore, access to overall CBT-I is perhaps essential as 
patients may respond individually to different components 
of CBT-I. A stepped care approach can provide access to 
patients who do not respond initially to low cost or manualized 
interventions. The self-help strategies facilitated by treatment 
modalities like the Internet may now be considered as the 
first port of call into the overall referral pathway of stepped 
care for insomnia.32,40 Recently, RCTs have evaluated the use 
of the Internet to deliver a standardized and low-cost form 
of CBT-I and found improvements in subjective measures of 
both sleep and daytime functioning.57,66 The integration of this 
approach into primary care is a current area of interest that 
should be adopted and evaluated for treatment efficacy; this 
aims to improve access to CBT-I and enable treatment to be 
the first approach to insomnia management.
Emerging therapies
Recently, new psychological treatments for insomnia have 
been proposed with preliminary evidence from clinical trials. 
The first is called intensive sleep retraining (ISR) and involves 
an in-laboratory protocol to recondition the automatic process 
of sleep initiation through multiple sleep onset trials. Retrain-
ing consists of 50 half-hourly sleep onset trials over a 25-hour 
sleep deprivation period. Each opportunity for sleep onset is 
limited to 20 minutes and stopped if sleep does not occur. If 
sleep does occur, it is limited to three consecutive minutes 
only and then the patient is awoken.67,68 The procedure is 
relatively novel and so far only one RCT has evaluated the 
efficacy of ISR. Treatment appeared to rapidly improve 
SOL and TST in those who were in the retraining condition 
combined with a behavioral intervention (SCT). Therefore, 
the findings have suggested that this in-laboratory protocol 
may quickly recondition the patient with insomnia to sleep-
promoting stimuli (bed, bedroom environment, and factors 
involved in sleep initiation). ISR may be a powerful and 
relatively fast way to administer what is normally achieved 
over a number of weeks with SRT and SCT procedures 
addressing the wake-promoting activities that have been 
paired with sleep onset.69 This intervention may also have 
therapeutic effects on cognitive processes associated with 
insomnia maintenance, including dysfunctional thoughts and 
beliefs about sleep and sleep effort. One limitation of this 
approach is the implementation of the experimental proce-
dure, which is costly due to the amount of time required in 
the laboratory. Therefore, ISR is in its infancy and further 
studies are required to examine the clinical effectiveness and 
provide a suitable method for patient delivery (eg, home-
based procedure).
Further research has looked at the contribution of com-
bining pharmacotherapy with CBT-I in order to increase 
adherence and the potentiation of treatment outcomes 
systematically. Morin et al34 evaluated the use of CBT-I 
combined with zolpidem compared to CBT-I alone and found 
enhanced benefits during the acute phase of therapy (first 
6 weeks) only. Long-term treatment was most effective with 
discontinuation of medication. One other previous study, how-
ever, found CBT-I to be more effective compared to combined 
therapy (CBT-I with zolpidem).70 Therefore, CBT-I should be 
considered the first-line intervention for insomnia, and hypnot-
ics may only produce short-term gains above CBT-I. These 
results reinforce previous findings regarding the short-term 
only use of pharmacotherapy for insomnia.27,35,71,72
One further development in the literature is to spe-
cifically target cognitive processes (worry and rumination; 
attentional bias/sleep-related monitoring; misperception of 
sleep and daytime deficits; unhelpful beliefs about sleep; 
use of safety behaviors) that operate both during the day 
and night to maintain insomnia. A preliminary open trial of 
cognitive therapy (CT) for insomnia found improvements in 
both nighttime and daytime factors, which were found to be 
maintained at 12 months follow-up, suggesting that this may 
be a useful therapy for insomnia.73 Harvey et al62 next looked 
to evaluate the use of CT as part of an RCT for the treatment 
of chronic insomnia with the aim of evaluating the individual 
contributions of behavior therapy and CT compared to overall 
CBT-I for insomnia. This study found that full CBT-I had the 
greatest improvements (proportion of treatment responders 
quantified by the insomnia severity index). Behavior therapy ChronoPhysiology and Therapy 2014:4 submit your manuscript | www.dovepress.com
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was found to have the fastest improvements but these were 
not maintained at 6 months follow-up, whereas gains with 
CT were the slowest but were found to be similar to CBT-I at 
follow-up. Therefore, this study suggests that CT is required 
for maintaining improvements in sleep.62 Further RCTs are 
now required to evaluate the specific treatment effectiveness 
of CT and newer “third-wave” treatment approaches, includ-
ing mindfulness.74,75
Conclusion
Insomnia is a common sleep disorder that impacts on both 
sleep and daytime functioning. CBT-I is an effective interven-
tion for the treatment of insomnia for sleep diary variables but 
more work is required and attention should be placed on further 
measures of subjective daytime   functioning and of objective 
sleep changes. Further research is required to systematically 
examine the clinical effectiveness of emerging therapies for 
insomnia through well-designed, large-scale RCTs.
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